Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS: Apalutamide in High-risk, Localized or Locally Advanced Prostate Cancer
NCT02531516Phase 3Active, not recruiting
- Sponsor
- Aragon Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands
- Countries
- 23
01
Overview
A Phase 3 trial of apalutamide in prostate cancer (PCa), sponsored by Aragon Pharmaceuticals. Started Nov 2015; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02531516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531516.